Skip to main content

Table 4 Propensity score weighted logistic regression of RSV-related hospitalization

From: Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis

Characteristic

Effect comparison

Full study population (N= 8443)

Subgroup population* (N= 8106)

  

Odds ratio

95% confidence limits

Odds ratio

95% confidence limits

Full prophylaxis

No vs. Yes

1.207

1.088

1.339

1.253

1.115

1.408

Gender

Male vs. Female

1.163

1.047

1.291

1.19

1.058

1.338

Race

Black vs. White

0.956

0.835

1.095

0.742

0.634

0.869

Hispanic vs. White

1.132

0.947

1.354

1.151

0.947

1.4

Other vs. White

1.214

1.044

1.412

1.219

1.034

1.438

Population density

Rural vs. Urban

1.375

1.222

1.549

1.378

1.208

1.573

Unknown vs. Urban

1.448

0.559

3.751

1.939

0.759

4.954

Blind or disabled basis of eligibility

Characteristic Present vs. Absent

1.012

0.846

1.212

0.953

0.781

1.163

Capitation indicator

Characteristic Present vs. Absent

1.269

1.121

1.437

1.292

1.124

1.486

Birth year

Year 2004 vs. 2003

0.914

0.784

1.064

0.889

0.75

1.053

Year 2005 vs. 2003

0.847

0.714

1.006

0.826

0.683

1

Year 2006 vs. 2003

0.899

0.742

1.09

0.894

0.724

1.105

Year 2007 vs. 2003

0.751

0.616

0.914

0.646

0.515

0.812

Year 2008 vs. 2003

0.929

0.771

1.119

0.865

0.702

1.067

Age at onset of RSV season

>3 months vs. ≤3 months

1.284

1.153

1.43

1.127

0.999

1.271

Gestational age

<32 weeks vs. 33–34 Weeks

1.012

0.734

1.395

0.977

0.667

1.433

35-36 weeks† vs. 33–34 Weeks

2.523

1.469

4.336

2.53

1.384

4.626

37+ weeks† vs. 33–34 Weeks

1.394

1.191

1.633

1.548

1.303

1.839

Gestational Age Unknown vs. 33–34 Weeks

1.226

1.063

1.414

1.178

1.004

1.383

Birth weight

<2500 grams vs. ≥2500 grams

0.879

0.636

1.216

0.918

0.634

1.329

missing vs. ≥2500 grams

1.043

0.74

1.47

0.977

0.659

1.449

Birth type

Multiplets vs. Singleton

0.944

0.815

1.094

0.813

0.686

0.963

Unknown vs. Singleton

0.86

0.7

1.057

0.763

0.602

0.966

NICU during birth admission

Characteristic Present vs. Absent

1.384

1.122

1.708

1.294

1.012

1.653

CLDP

Characteristic Present vs. Absent

2.033

1.789

2.311

1.89

1.635

2.186

CHD

Characteristic Present vs. Absent

1.494

1.275

1.751

1.551

1.292

1.86

Comorbidity other than CHD, CLDP

Characteristic Present vs. Absent

1.407

1.252

1.581

1.511

1.323

1.727

RSV-related admission prior to season

Characteristic Present vs. Absent

1.439

1.128

1.835

3.531

0.806

15.47

Inpatient admission or emergency room visit prior to first dose

Characteristic Present vs. Absent

2.521

2.253

2.82

1.727

1.531

1.948

  1. Bold indicates statistically significant results.
  2. *Excluding infants with any RSV-related admission that occurred prior to prior to first palivizumab dose AND prior to November 30.
  3. †Infants with gestational age >34 weeks also had either CLDP or CHD.
  4. CHD: Congenital heart disease; CLDP: Chronic lung disease of prematurity; NICU: Neonatal intensive care unit; ED: Emergency department.
Back to article page

BMC Pediatrics

ISSN: 1471-2431

Contact us